Since its inception in the 1980s, genetic engineering has evolved to become a high-precision tool in medicine. The advent of technologies such as CRISPR-Cas9 and its advancement towards systems such as prime editing and the recently developed bridge recombination has unlocked an unprecedented range of therapeutic possibilities. However, these advances also pose important ethical challenges, especially when considering their application in embryos or germ cells. This article analyzes the current state and future perspectives of gene editing from a bioethical perspective.

The genetic engineering developed in the 1980s sought to directly modify the molecules carrying genetic information – DNA and RNA – in order to alter the genetic characteristics of their carriers outside of their sexual cycle (1). The technology that made this possible emerged when scientists managed to isolate, clone and manipulate nucleic acids, enabling DNA molecules to be transferred from one cell to another – even between different species – and laying the foundations for the development of “transgenic” or genetically modified organisms (GMOs), whose applications have benefited the pharmacological industry, agriculture, livestock farming, and medicine.

A major milestone in the progression of genetic engineering was its application in humans to cure genetic diseases, a practice known as “gene therapy”. The Human Genome Project, completed in April 2003, has played a key role in reaching this objective, together with the development of a series of techniques designed to systematically modify the genomic regions responsible for diseases.

The field of gene therapy includes several types of procedures that still need further refinement to improve their efficacy with the required level of precision and safety. Its goals include the insertion of a gene or DNA sequence into the genome, modifying the expression level of a faulty gene, or silencing or correcting the faulty gene using gene editing technology. These techniques can be applied to the DNA of any type of human cells, both ex vivo – taking advantage of advances in Cell Biology that allow in vitro culture – and in vivo, by acting directly on the patient’s tissues and cells, both somatic and germ cells. The ethical implications of these actions differ, since modifications in the somatic cells only affect the individual in whom they are carried out, while any unintended alteration in the germ cells can be passed on to future generations.

CRISPR-Cas9 gene editing

Although several techniques have been developed using different approaches, costs and effectiveness, CRISPR-Cas9 gene editing – first proposed by researchers Jennifer Doudna and Emmanuelle Charpentier in 2013 (2) – is undoubtedly the method that has garnered the most interest due to its superior simplicity and precision. Doudna and Charpentier were subsequently awarded the 2020 Nobel Prize in Chemistry for their work in this field.

CRISPR-Cas9 is based on the discovery by Spanish microbiologist Francisco Juan Martínez Mojica of a region in the genome of bacteria and archaea that he called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), involved in the defense against attacks by bacteriophage viruses and foreign DNA (3). The system works by combining two elements: synthesis of a guide RNA, to recognize the invading DNA; and the action of an endonuclease enzyme bound to it, called Cas, which targets the invading DNA and cuts it. As a natural mechanism, microorganisms take advantage of this action to eliminate foreign DNA.

Although CRISPR is a natural mechanism, functioning as an immune system in bacteria, researchers have learned to use it in the laboratory as a tool to recognize and target any DNA region of known sequence. As a methodology applied in gene therapy, it involves mimicking the natural mechanism to cut a DNA region responsible for a genetic alteration, thus creating the conditions necessary for its subsequent repair or silencing.

The CRISPR-Cas9 technique initially developed involves cutting the DNA at the region responsible for a phenotypic alteration through recognition by a specifically synthesized RNA molecule, the guide RNA. The Cas9 enzyme binds to the guide RNA, which directs Cas9 to the target site, where it cuts the DNA at a specific location. The nuclease induces a break at the same position in the two strands of the molecule (double-strand break, DSB), thereby triggering mechanisms to repair the cut DNA.

There are two main mechanisms of DNA repair, depending on whether or not the broken ends have complementary single-stranded regions. Based on this, homology-directed repair (HDR) – also known as homologous recombination (HR) – or non-homologous end-joining (NHEJ) may occur. The outcome is different, since HR results in restoration of the cut site without causing physical alteration of the DNA, whereas NHEJ is prone to introducing errors, such as base insertions and deletions. These can produce frameshift mutations in the DNA reading frame and premature stop codons in gene translation, resulting in the functional deactivation of a gene. Accordingly, this mode of action is called CRISPR interference. Most gene editing approaches aim to induce DSBs followed by HR to correct the altered sequence by providing the cells with a DNA molecule analogous to the break site sequence for use as a template for repair. In contrast, NHEJ repair tends to generate insertion or deletion errors in DNA regions, known as indels, which may eventually be of interest if the goal is inactivation of the faulty gene (knockout). CRISPR interference has multiple applications, both basic (for example, to learn about the functions of genes) and applied (for example, to silence an oncogene).

To edit the target DNA sequence, two molecular components are required: a guide RNA to recognize the target DNA to be edited or silenced, and the enzyme Cas9 nuclease. Thanks to the availability of genomic databases, the RNA can be designed and specifically synthesized in the laboratory to recognize the target DNA sequences. The nuclease most commonly teamed with the guide RNA is Streptococcus pyogenes Cas 9, but there are other alternatives, such as Cas13 isolated from Leptotrichia shahii (4) or others.

To edit a gene or sequence at any DNA locus, both specified elements must be introduced into the target cells (the guide RNA and the enzyme Cas9) using the appropriate vectors. Viruses are commonly used for this purpose, after being previously disarmed by removing regions of their genome that could affect the recipient cells, such as attenuated retroviruses and adenoviruses, lentiviruses, etc. In recent years, non-viral vectors have been developed, such as lipid nanoparticles, carbon nanotubes, liposomes and electroporation, plasmids, microinjection and others (5).

Once inside the cells, the guide RNA recognizes the target DNA and the Cas9 enzyme cuts it, producing the DSB. Although in vivo use would be ideal, for technical and safety reasons, the editing is often carried out in vitro, in cells extracted from the patient themselves and cultured in the laboratory.

In a previous article entitled CRISPR-Cas9, the revolution in the treatment of genetic diseases, we explain these techniques in further detail, as well as their application in gene therapy to treat some diseases, such as cancer, monogenic diseases, etc. A further discussion of these issues was the subject of a presentation at the Genetics Congress held in July 2024 at the Catholic University of Valencia.

The technology is not without difficulties as regards its precision and safety, giving rise to a number of uncertainties. Consequently, this has necessitated the development of modifications to the technique, as well as new research and clinical trials to ensure safety and efficacy, a prerequisite for approval by national and international medicines agencies.

One year ago, amid high expectations, we stood on the threshold of the second generation of CRISPR technology for therapeutic use. In recent months, technological innovations have emerged that broaden the outlook and enable new applications to be pursued and expanded.

Goal: improve precision. Innovation: prime editing

Although the precision of CRISPR-Cas9 technology is high in terms of recognizing the target DNA to be removed or edited, it is less precise in the subsequent repair process, potentially resulting in uncorrected errors or other off-target effects. As a result, there are safety issues, so novel methods have been developed to improve both effectiveness and accuracy in an attempt to reduce errors.

In 2019, a variant of the technology, known as Prime-Editing (6), was developed. This new technique uses a modified nuclease to cut only one of the two DNA strands instead of causing a DSB. Another development was the use of a programmable nickase enzyme fused to a reverse transcriptase enzyme, and an extended guide RNA that both specifies the target site and templates the desired genome edit. The RNA sequence is programmed by artificial synthesis to target a specific region of the genome. Once this region is recognized, a triplex is formed with the two strands of the target DNA and synthesis of the DNA to be edited is initiated using the RNA as a template.

This new technology has undergone preclinical and indeed clinical trials. Thus, the company Prime Medicine, which conducted successful preclinical trials in mice, sponsored the first clinical trial of the use of Prime Editing, called PM359, which was approved in 2019. The study aimed to correct a rare monogenic recessive disorder, chronic granulomatous disease (CGD) (7). This life-threatening disease is due to an immune deficiency characterized by bacterial and fungal infections, and results from the lack of functionality of the neutrophils responsible for defending against these types of infectious agents. Although it is still too early to assess the outcome, after transplantation of Prime Edited patient autologous CD34+ cells in an 18-year-old with CGD, no side effects were recorded after 1 month. Most importantly, cellular therapy was noted when the functionality of the gene responsible for synthesizing the enzyme involved in the disease was observed in most of the cells. The trial investigators indicated that this level of restoration is sufficient to provide a major boost to the patient’s immune system. Nevertheless, a significant degree of uncertainty remains. As such, further evidence from new clinical trials is required, and outcomes must be studied over a longer period of time.

In principle, everything seems to point to a substantial improvement in Prime Editing with respect to the initial CRISPR-Cas9 technique. This is due to its greater versatility, specificity and precision, especially since it does not require double-strand DNA breaks and because of its ability to make practically any substitution, small insertion or small deletion in the DNA of the treated cells.

Beyond CRISPR. “Bridge editing” or “bridge recombination”

A few months ago, the journal Nature published a novel CRISPR-based technology, but with a broader perspective in terms of the size of the target DNA region.

This new system is based on a different molecular mechanism called “transposition”. Transposition is a natural phenomenon of great evolutionary importance due to its role in genome remodeling. The mechanism is based on the ability of so-called “mobile elements”, or “transposable elements” – segments of DNA of variable length – to move, expand and produce deletions, additions or inversions in the genome of many species, which constitutes a natural way of generating genetic diversity. It was discovered in the 1950s by American researcher Barbara McClintock (1902-1992) from Cornell University. The discovery was made in the maize (corn) plant, although it was later shown to be universal in all types of species. While Dr. McClintock’s research was initially given little recognition, it was eventually accepted after she demonstrated its existence in bacteria, a finding for which she was awarded the 1983 Nobel Prize in Medicine (8). The chromosomal rearrangements attributed to mobile elements or “jumping genes”, as Dr. McClintock calls them, are usually orchestrated by enzymes involved in fundamental DNA repair processes, such as HR, or the transposition of foreign genetic material by viruses or other sources of invasive DNA.

The human genome contains several types of these transposable elements that form part of the non-coding genome. These are repetitive sequences scattered throughout the genome of many species, from prokaryotes to mammals and higher plants. In the case of the human genome, there may be more than 2,000,000 of these elements that have accumulated over the course of evolution and that now make up a significant percentage of our genome. A unique feature of these elements is their ability to move and change place in the genome through enzymes called transposases, integrases, endonucleases, and recombinases, which can be self-encoded.

An insertion sequence (IS) is a type of small mobile element that is abundant in the genome of bacteria and archaea. These IS elements, of which there are many different types, use a self-encoded transposase that recognizes sites that have inverted terminal repeats (such as those that often occur in DSB sites) through protein-DNA interactions​​.

Building on these elements, a team led by researcher Patrick Hsu from the Department of Bioengineering at the University of California at Palo Alto developed a technology called “bridge recombination” [9], so called due to the fact that it facilitates the connection between two DNA regions, in which the insertion element IS110 mediates. IS110 is a type of autonomous mobile element, and it has been found that, when it excises itself from the region it occupies in the genome, the non-coding DNA ends are joined together to produce an RNA molecule (the bridge RNA) that folds into two loops. IS110 also expresses a self-encoded recombinase, which binds to the RNA. The bridge RNA contains two internal loops that encode nucleotide stretches that base-pair: one with the target DNA and the other with the donor DNA, which is the IS110 element itself. Hsu and coworkers demonstrated that target and donor binding loops can be independently reprogrammed to direct sequence-specific recombination between two DNA molecules. The study published in Nature demonstrates that target and donor binding loops can be independently reprogrammed, constituting a bispecific guide RNA to direct recombination between two DNA molecules.

The modularity enables insertion of DNA into specific genomic target sites, as well as programmable excision and inversion of DNA. This means that the system can be used to insert any desired genetic payload into specific genomic targets, including a functional copy of a gene at the site of a defective disease-causing version, or at any other genomic location.

Technological perspectives and bioethical implications

The IS110 bridge recombination system expands the diversity of nucleic acid-guided systems beyond CRISPR and offers a unified mechanism for the three fundamental DNA rearrangements required in genome editing: insertions, deletions, and inversions. Bridge recombination would allow the insertion of longer DNA sequences than those currently facilitated by CRISPR at the desired genomic target sites, including entire genes. This is a particularly important advantage over CRISPR-Cas9 and Prime Editing, as there are genes involved in diseases that have many different alleles. i.e., different altered versions of the same gene. The bridge editing application would avoid having to design different guide RNAs for each type of allele to be edited, since the entire gene could be replaced.

Bridge recombination using mobile elements could become a precise and powerful tool for programmable DNA recombination and rearrangement. By making it possible to specify any target genomic sequence and any donor DNA molecule to be inserted into a recipient genome, this technology broadens the field of therapeutic applications beyond what CRISPR-Cas9 offers.

Although this technological approach is yet to be tested in human cells, if successful, it would mark a significant improvement over the already great potential of CRISPR-Cas9 technology. Despite its excellent prospects, bridge RNA could open the door to other aspects of genetic modification for undesirable purposes, as it is an invitation to implement riskier genomic designs, such as those contemplated by transhumanists and synthetic biologists. It is therefore important to be extremely vigilant with regard to research objectives and to enforce the precautionary principle along with the necessary bioethical restrictions, especially regarding any proposed work in human embryos and germ tissue.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

 

References:

(1)  Rieger, R. Michaelis, A..Green. M.M. Glossary of Genetics and Cytogenetics. Springer-Verlag, 1976, Berlin.

(2) Doudna, J.A., Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346 (6213), 1258096

(3)  Mojica, F.J. Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning. Mol. Microbiol. 17, 1995: 85–93.

(4)   Komor, A.C. et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 2016: 420–424.

(5)  Wang, D., Zhang, F., Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 2020: 136–150.

(6) Scholefield, J., Harrison, P.T. Prime editing – an update on the field. Gene Ther, 28, 2021: 396–401.

(7) Chen, P.J., Liu, D.R. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 24(3), 2023: 161- 177

(8)  McClintock, B. The origin and behavior of mutable loci in maize. Proc. Natl Acad. Sci. USA 36, 1950: 344–355.

(9) Durrant, M.G., Perry, N.T., Pa.i, J.J. et al. Bridge RNAs direct programmable recombination of target and donor DNA. Nature 630 , 2024: 984–993.

 

Share This Story, Choose Your Platform!